AGP Executive Report
Last update: 8 hours agoClinical Trial Update (Australia): Avecho’s independent monitoring board reviewed unblinded interim data from its pivotal cannabidiol insomnia trial and unanimously backed continuing recruitment at the original participant size, with the company restarting final-stage enrollment and securing a long-term exclusive generics license deal covering Australian commercial rights. Regulatory Pathway (Autism): Neurotech International says its registrational autism program is in pivotal recruitment, with a U.S. regulatory clearance opening a parallel dosing study that could support a single evidence package across jurisdictions. Care Delivery Expansion (Mental Health): Emyria extended its Empax clinic network across mainland states, including western Sydney, supported by a private health insurance reimbursement pathway rather than purely out-of-pocket demand. Policy & Governance (Colombia): A new study maps how medicinal cannabis research can be translated into workable policy, linking evidence with Ministry of Health decision-making on access rules and psychoactive limits. Hemp THC Retail (U.S.): Convenience stores are pushing for a regulatory alternative after a federal delay on a hemp THC ban, arguing existing age-verification systems can support legal sales. Cybersecurity (U.S./Canada): An FBI probe follows reports of massive driver’s license data exposure tied to an ID verification firm, raising risks for fraud that can hit regulated cannabis businesses too.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
